CuraTeQ Biologics gets Health Canada approval for Bevqolva cancer treatment

Business May 01, 2026

CuraTeQ Biologics, part of Aurobindo Pharma, just got the go-ahead from Health Canada to sell Bevqolva, a biosimilar version of the cancer drug Avastin.
This means Bevqolva is officially cleared for use in treating several types of cancer, meeting all the safety and quality standards set by Canadian regulators.

CuraTeQ has 2 biosimilars under review

Bevqolva works by blocking new blood vessels that help tumors grow, making it a key option for cancer treatment.
This approval is a big step for CuraTeQ as it expands its lineup of biosimilars. It also has two more similar drugs under review in Canada.